



## Disclosures

### Personal Commercial (63)

Company Name	Relationship Category	Compensation Level	Topic Area(s)
<i>Self</i>			
Abbott Laboratories	Research/Research Grants	Significant (>= \$5,000)	
Agiros Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	
AHA	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Alexion Pharma	Research/Research Grants	Significant (>= \$5,000)	
Alnylam	Research/Research Grants	Significant (>= \$5,000)	
Amgen Inc.	Research/Research Grants	Significant (>= \$5,000)	Prevention
Angionetics	Research/Research Grants	Significant (>= \$5,000)	
Anthos Therapeutics	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
ARCA	Research/Research Grants ‡ ASPEN COVID 19	Significant (>= \$5,000)	Other
ARCA biopharma, Inc.	Research/Research Grants ‡ ASPEN COVID 19	Significant (>= \$5,000)	Pulmonary Hypertension and Venous Thromboembolic
Array	Research/Research Grants	Significant (>= \$5,000)	
AstraZeneca Pharmaceuticals	Research/Research Grants ‡ PEGASUS-TIMI 54, REAL-TIMI 63B, ALETHEIA real world dataset	Significant (>= \$5,000)	Prevention
Atentiv	Research/Research Grants	Significant (>= \$5,000)	
Audentes	Research/Research Grants	Significant (>= \$5,000)	
Bayer	Research/Research Grants ‡ VOYAGER PAD	Significant (>= \$5,000)	Prevention
Better Therapeutics	Research/Research Grants	Significant (>= \$5,000)	Prevention
Brigham and Women's Hospital	Research/Research Grants	Significant (>= \$5,000)	
Bristol-Myers Squibb Company	Research/Research Grants	Significant (>= \$5,000)	
Cambrian Biopharma	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Cardiol Therapeutics	Research/Research Grants	Significant (>= \$5,000)	
CellResearch	Research/Research Grants	Significant (>= \$5,000)	
Cleerly	Other - Grant support to CPC	Significant (>= \$5,000)	Prevention
Cook Regentec	Research/Research Grants	Significant (>= \$5,000)	
CSL Behring	Research/Research Grants	Significant (>= \$5,000)	
Eidos Therapeutics	Research/Research Grants	Significant (>= \$5,000)	
EP Trading Company	Research/Research Grants	Significant (>= \$5,000)	
EPG Communications	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Modest (< \$5,000)	
Epizon Pharma	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Esperion	Research/Research Grants	Significant (>= \$5,000)	
EverlyWell	Research/Research Grants	Significant (>= \$5,000)	
Faraday Pharmaceuticals	Research/Research Grants	Significant (>= \$5,000)	

Company Name	Relationship Category	Compensation Level	Topic Area(s)
Fortress Biotech	Research/Research Grants	Significant (>= \$5,000)	Prevention
Heartflow	Research/Research Grants	Significant (>= \$5,000)	
Insmed	Research/Research Grants	Significant (>= \$5,000)	
Janssen Pharmaceuticals, Inc	Research/Research Grants ‡ PREVENT HD, VOYAGER PAD	Significant (>= \$5,000)	
Kowa Research	Research/Research Grants	Significant (>= \$5,000)	
Lexicon	Research/Research Grants	Significant (>= \$5,000)	Other
Medtronic	Stock	Modest (< \$5,000)	
Merck & Co., Inc.	Research/Research Grants	Significant (>= \$5,000)	
Moderna	Research/Research Grants	Significant (>= \$5,000)	
NIH	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Novartis Corporation	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	Vascular Medicine
NovoNordisk	Research/Research Grants	Significant (>= \$5,000)	
Pfizer Inc	Stock	Modest (< \$5,000)	
Pfizer Inc	Research/Research Grants	Significant (>= \$5,000)	
PhaseBio	Research/Research Grants	Significant (>= \$5,000)	
PPD Development	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
Prothena Biosciences	Research/Research Grants	Significant (>= \$5,000)	
Regeneron	Research/Research Grants	Significant (>= \$5,000)	
Regio Biosciences	Research/Research Grants	Significant (>= \$5,000)	
Sanifit	Research/Research Grants	Significant (>= \$5,000)	
Sanofi-Aventis	Research/Research Grants	Significant (>= \$5,000)	Other
Silence Therapeutics	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
St. Luke's Hospital of Kansas City	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Stealth BioTherapeutics	Research/Research Grants	Significant (>= \$5,000)	
Thrombosis Research Institute	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
University of Colorado	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
University of Pittsburgh	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
VarmX	Other - Research grant/consulting funding to CPC, of which Dr. Bonaca is Executive Director	Significant (>= \$5,000)	
Vertex Pharmaceuticals	Stock	Significant (>= \$5,000)	
Worldwide Clinical Trials	Research/Research Grants	Significant (>= \$5,000)	
Wraser	Research/Research Grants	Significant (>= \$5,000)	Vascular Medicine
Yale Cardiovascular Research Group	Research/Research Grants	Significant (>= \$5,000)	

Additional Personal Commercial Disclosures for Education Activities (0)

No disclosures on record

Personal Organizational or Other Non-Commercial (0)

No disclosures on record

Clinical Trial Enroller (0)

No disclosures on record

Institutional Financial Decision-Making Role (0)

## Expert Witness Testimony (1)

Year	Case Title	Represented	Description	Compensation
Self				
2013	aortic dissection	Defendant	Missed aortic dissection	Significant (>= \$5,000)

† Commercial Funding Source | ‡ Trial Name

## Agreement

### Certified Education Attestation | Signed on 1/9/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/CertifiedEducationAttestationAgreement>

### Confidentiality, Disclosure and Assignment Agreement | Signed on 1/9/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/ConfidentialityDisclosureandAssignmentAgreement>

### Embargo | Signed on 1/9/2024

URL for full agreement: <http://disclosures.acc.org/Public/Definition/EmbargoAgreement>

### On-Going Obligation Agreement | Signed on 1/9/2024

## ACC and Disclosures

ACC is committed to ensuring balance, independence, objectivity, and scientific rigor in their governance, programmatic, educational, chapter, and other activities. Fulfilling this commitment depends on member and public confidence in the College's integrity and objectivity. The College recognizes that the activities of College members in their practice, research, and other volunteer and private endeavors could lead to the development of conflicts of interest. Therefore, the College has established a Disclosure Policy and conflict of interest management process as appropriate. All members involved in College governance, including all committees and task forces, programmatic, certified educational, chapter, and other activities must provide complete, timely, accurate, and signed disclosure statements. Compliance with this process is mandatory for participation in College activities.